CYTOGENIX, INC. (CYGX.PK-News) announced today that it has appointed Campbell Murray, MD to its Board of Advisors.

Campbell Murray, MD: Campbell currently serves as a director on the boards of Aileron Therapeutics, Akebia Therapeutics, Alios BioPharma, BioRelix, Euthymics Bioscience, ProCertus BioPharm and Tokai Pharmaceuticals and as an observer on the board of MicroCHIPS and Tepha. Campbell, is a New Zealand trained physician, Kauffman Fellow and holds an MBA from Harvard Business School and an MPP (public policy) from the John F. Kennedy School of Government where he was a Knox Fellow and Rotary Ambassadorial Scholar.

Lex Cowsert, CEO of CytoGenix stated, “Having Dr. Murray join the CytoGenix Board of Advisors adds significant benefit and enhances our extremely talented team of Advisors, who all embrace his admission to the Board of Advisors. Campbell's vast experience is a tremendous asset which will help CytoGenix advance its product line on a global platform, which can only add to shareholder value.”

CytoGenix, Inc.

CytoGenix is a Nevada public corporation traded under the symbol CYGX.PK. CytoGenix is a biotechnology company developing biotechnology derived products for vaccines and therapeutic applications for human, agricultural and veterinary markets. As such, CytoGenix has access to a broad range of biological expertise that can be leveraged to identify, evaluate, develop and commercialize biologically based technologies for energy production.

Safe Harbor Statement

The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Important factors, including general economic conditions, spending levels and other factors could cause actual results to differ materially from the Company's expectations.